Cargando…

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, James P., Joshua, Anthony M., da Silva, Ines P., Dummer, Reinhard, Goldinger, Simone M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164011/
https://www.ncbi.nlm.nih.gov/pubmed/36988735
http://dx.doi.org/10.1007/s11912-023-01385-6
_version_ 1785038000750592000
author Pham, James P.
Joshua, Anthony M.
da Silva, Ines P.
Dummer, Reinhard
Goldinger, Simone M.
author_facet Pham, James P.
Joshua, Anthony M.
da Silva, Ines P.
Dummer, Reinhard
Goldinger, Simone M.
author_sort Pham, James P.
collection PubMed
description PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. RECENT FINDINGS: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. SUMMARY: Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients.
format Online
Article
Text
id pubmed-10164011
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101640112023-05-08 Chemotherapy in Cutaneous Melanoma: Is There Still a Role? Pham, James P. Joshua, Anthony M. da Silva, Ines P. Dummer, Reinhard Goldinger, Simone M. Curr Oncol Rep Article PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. RECENT FINDINGS: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. SUMMARY: Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients. Springer US 2023-03-29 2023 /pmc/articles/PMC10164011/ /pubmed/36988735 http://dx.doi.org/10.1007/s11912-023-01385-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pham, James P.
Joshua, Anthony M.
da Silva, Ines P.
Dummer, Reinhard
Goldinger, Simone M.
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
title Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
title_full Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
title_fullStr Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
title_full_unstemmed Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
title_short Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
title_sort chemotherapy in cutaneous melanoma: is there still a role?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164011/
https://www.ncbi.nlm.nih.gov/pubmed/36988735
http://dx.doi.org/10.1007/s11912-023-01385-6
work_keys_str_mv AT phamjamesp chemotherapyincutaneousmelanomaistherestillarole
AT joshuaanthonym chemotherapyincutaneousmelanomaistherestillarole
AT dasilvainesp chemotherapyincutaneousmelanomaistherestillarole
AT dummerreinhard chemotherapyincutaneousmelanomaistherestillarole
AT goldingersimonem chemotherapyincutaneousmelanomaistherestillarole